- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06151600
A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J (CMT4J)
November 23, 2023 updated by: Elpida Therapeutics SPC
This is a multicenter, longitudinal, prospective observational natural history study of subjects with a molecularly confirmed diagnosis of CMT4J.
The study will enroll 20 subjects of any age into a uniform protocol for follow-up and evaluations.
Subject visits will occur every 12 months + 4 weeks for up to 2 years.
Study Overview
Status
Not yet recruiting
Detailed Description
This is a multicenter, longitudinal, prospective observational natural history study of subjects with a molecularly confirmed diagnosis of CMT4J.
The study will enroll 20 subjects of any age into a uniform protocol for follow-up and evaluations.
The study will obtain demographic and medical history information.
Natural history data will be collected prospectively on an annual basis and may include physical/neurological exams, standard laboratory tests, CMT outcome and disability measures, neuropsychological tests, nerve conduction studies (NCS), and imaging studies (muscle MRI).
Pulmonary function test (PFT) and scoliosis series x-ray Subject visits will occur every 12 months + 4 weeks for up to 2 years.
Subjects who terminate from the study prior to Visit 3 will undergo an early termination/end of study visit (EOS) if possible.
The early termination/end of study visit is comprised of the Visit 3 assessments.
If needed, the Investigator may conduct unscheduled visits with Sponsor's approval.
No investigational product will be used during the study.
Study Type
Observational
Enrollment (Estimated)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Souad Messahel, Ph.D
- Phone Number: 4157255245
- Email: souad@elpidatx.com
Study Contact Backup
- Name: Keith Gottlieb, Ph.D
- Phone Number: 4157255245
- Email: keith@elpidatx.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Subjects with a genetically confirmed diagnosis of CMT4J will be included.
Description
Inclusion Criteria:
- Male or female, all ages
- A molecularly-confirmed diagnosis of CMT4J (confirmed by a CLIA certified, CE-marked, or equivalent lab): Genomic DNA mutation analysis demonstrating 1) bi-allelic pathogenic and/or likely pathogenic variants (by ACMG criteria) in the FIG4 gene, or 2) bi-allelic variants with one pathogenic and/or likely pathogenic variant in trans with a variant of uncertain significance if laboratory evidence and expert consensus exits in support of loss of FIG4 function exists.
- Informed consent from patients 18 years or older who are able to provide consent and from caregivers; parent(s)/guardian(s) providing consent for subjects younger than 18 years at Screening and patients older than 18 years unable to provide informed consent
- Informed assent of patients younger than 18 years at Screening who are able to provide assent
- Able and willing to comply with the study protocol, including travel to Study Center, procedures, measurements and visits
Exclusion Criteria:
- Any known genetic abnormality, including chromosomal aberrations that confound the clinical phenotype
- Current participation in an interventional or therapeutic study
- Receiving an investigational drug within 90 days of the Baseline Visit
- Prior or current treatment with gene or stem cell therapy
- Any other diseases which may significantly interfere with the assessment of CMT4J
- Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the subject unsuitable for inclusion or could interfere with the subject participating in or completing the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Study objective
Time Frame: 2 years
|
This study is designed to investigate the clinical characteristics and natural history of CMT4J.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 1, 2024
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
March 1, 2028
Study Registration Dates
First Submitted
October 23, 2023
First Submitted That Met QC Criteria
November 23, 2023
First Posted (Actual)
November 30, 2023
Study Record Updates
Last Update Posted (Actual)
November 30, 2023
Last Update Submitted That Met QC Criteria
November 23, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Stomatognathic Diseases
- Heredodegenerative Disorders, Nervous System
- Nervous System Malformations
- Polyneuropathies
- Peripheral Nervous System Diseases
- Neurodegenerative Diseases
- Tooth Diseases
- Neuromuscular Diseases
- Nerve Compression Syndromes
- Charcot-Marie-Tooth Disease
- Hereditary Sensory and Motor Neuropathy
Other Study ID Numbers
- ELPIDA THERAPEUTICS CMT4J NHS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified data for publication.
IPD Sharing Time Frame
Starting in January 2025
IPD Sharing Access Criteria
All Investigators leading the trial.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuromuscular Diseases
-
Brugmann University HospitalCompletedAnesthesia, General | Neuromuscular Transmission DisordersBelgium
-
University Hospital, ToursCompletedNeuromuscular Diseases in Children | Neuromuscular Diseases in InfantsFrance
-
National Institute of Nursing Research (NINR)TerminatedNeuromuscular DiseaseUnited States
-
Landon Pediatric FoundationCompleted
-
Institut de Myologie, FranceCompleted
-
Ottawa Hospital Research InstituteRecruiting
-
University of FloridaTerminated
-
Penwest Pharmaceuticals Co.TerminatedNeuromuscular DiseaseUnited Kingdom
-
Centre d'Investigation Clinique et Technologique...Association Française contre les Myopathies (AFM), ParisCompletedCommunication | Neuromuscular DiseaseFrance